BKBarina Khan

Barina Khan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Barina Khan has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeted Therapies and Imaging Biomarkers: Revolutionizing ITP and Coronary Inflammation Management

    by Aneesh Kumar Sangtiani, Barina Khan, Sundal Javed, Sariya Aamir

    Precision medicine is increasingly shaping clinical practice in both hematology and cardiology by promoting therapies and diagnostics rooted in disease mechanisms. In immune thrombocytopenia (ITP), rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, represents a targeted strategy that addresses key drivers of the disease. By reducing autoantibody production and limiting immune-mediated platelet destruction, it has demonstrated sustained platelet responses while potentially avoiding the broader immunosuppressive effects seen with conventional treatments. Its mechanism also raises the possibility of application in other autoimmune conditions. In cardiology, attention has turned toward pericoronary adipose tissue (PCAT) attenuation measured on coronary computed tomography angiography as a marker of coronary inflammation. Unlike traditional imaging that focuses primarily on luminal narrowing, PCAT assessment offers insight into vascular inflammatory activity and may enhance cardiovascular risk prediction. Although these developments are promising, important challenges remain, including long-term tolerability, cost considerations, and technical standardization. Together, these advances reflect both the opportunities and the complexities involved in translating precision medicine from theory into everyday clinical care.

  • Paclitaxel in oncology: balancing anticancer efficacy with potential carcinogenic risks and resistance mechanisms

    by Abdullah Saad, Barina Khan, Ahmed Reda Bahr, Mostafa Abdelhakiem

    Paclitaxel is a cornerstone of systemic cancer therapy because of its potent cytotoxic and immunomodulatory properties. By stabilizing microtubules and inducing mitotic arrest, it exerts broad efficacy against breast, ovarian, lung, pancreatic, and other epithelial malignancies. However, its therapeutic impact is limited by multifactorial resistance mechanisms and emerging concerns regarding its potential genotoxicity. The multifactorial resistance is mediated through ABCB1/P-glycoprotein efflux, β-tubulin mutations, apoptotic escape, nuclear envelope stiffening, and tumor microenvironment adaptations, including hypoxia and mechanotransduction. However, its broad utility among various tumors, the potential carcinogenic risk. Major risks are neutropenia, myelosuppression, peripheral neuropathy, arthralgia/myalgia, and hypersensitivity reactions, in addition to reported cases of therapy-related myeloid neoplasms (t-MDS/t-AML) following taxane-containing regimens. To achieve higher responses upon treating with paclitaxel, enhance drug delivery, overcome efflux, and mitigate toxicity, advances in nanoparticles, monitoring, managing risky patients, and perspectives to overcome the resistance have been explored. Paclitaxel exemplifies the therapeutic paradox of chemotherapy-an indispensable agent whose long-term safety and resistance landscape require continued biomarker-guided optimization and precision delivery strategies. This narrative review aims to balance the benefit-to-risk value of paclitaxel through the preclinical and clinical evidence on paclitaxel's dualistic profile, including its antitumor mechanisms, pathways of resistance, and theoretical carcinogenic risks, management of low and high-risk patients, in addition to great future approaches opening more hopes for paclitaxel use in more cancers.

  • Emerging Links Between PFAS Exposure and Autoimmune Thyroid Disease: A Narrative Review of Epidemiologic Evidence, Mechanistic Insights, and Research Gaps

    by Abdullah Nadeem, Muddassir Syed Saleem, Amara Ahmad Rai, Barina Khan, Areeba Shafqat, Fatima Tuz Zahra, Zoha Saeed, Mahnoor Umar, Ahmed Asad Raza, Nabahat Shafi, et al.

    Per‐ and polyfluoroalkyl substances (PFAS) are persistent synthetic chemicals widely distributed in the environment and human tissues. Known as endocrine‐disrupting chemicals, PFAS are increasingly investigated for their potential role in the rising global prevalence of autoimmune thyroid diseases (AITDs), such as Hashimoto's thyroiditis and Graves' disease. This narrative review synthesizes epidemiologic evidence and mechanistic insights to clarify this relationship. Epidemiologic findings remain heterogeneous; while some studies link PFOA and PFOS exposure to altered circulating thyroid hormones (e.g., increased FT3 and FT4), others report reduced T4 levels, particularly in vulnerable pregnant and neonatal populations. Mechanistically, PFAS interfere with thyroid homeostasis by disrupting iodide uptake via the sodium/iodide symporter (NIS), competing for transport proteins like transthyretin, and activating nuclear receptors like PPARα. Furthermore, PFAS promote immune dysregulation by modulating cytokine production and inducing oxidative stress, creating a microenvironment conducive to autoimmunity. Despite these biological plausibilities, many studies are limited by cross‐sectional designs and a lack of direct clinical AITD correlation. Future longitudinal research is essential to establish causality and guide public health interventions regarding environmental PFAS contamination.

  • Open Access

    Andembry (Garadacimab-gxii): A Novel Monoclonal Antibody for Preventing Hereditary Angioedema Attacks

    by Barina Khan, Mahnoor Abbas, Hifza Shahzad, Lubaba Amaim

    Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by recurrent, potentially life-threatening episodes of angioedema affecting the skin, gastrointestinal tract, and airway. It results from dysregulation of the kallikrein–kinin system due to C1-esterase inhibitor deficiency or dysfunction, leading to excessive bradykinin production and increased vascular permeability. Despite advances in prophylactic therapies such as C1-INH replacement, kallikrein inhibitors, and bradykinin receptor antagonists, limitations including frequent dosing, breakthrough attacks, and variable response, remain. Garadacimab is a novel fully human monoclonal antibody that targets activated factor XII (FXIIa), inhibiting initiation of the contact activation pathway upstream of bradykinin generation. Blocking FXIIa, it prevents prekallikrein activation and downstream inflammatory cascade amplification. Clinical trials across Phase 1–3 studies demonstrate consistent pharmacodynamic target engagement, dose-dependent suppression of the kallikrein pathway, and significant reductions in attack rates, with a substantial proportion of patients remaining attack-free. The pivotal Phase 3 (VANGUARD) study further confirmed sustained efficacy and meaningful improvements in health-related quality of life. Garadacimab has shown a favorable safety profile, with mostly mild to moderate adverse events and no major safety concerns. Its long half-life enables once-monthly subcutaneous administration, potentially improving adherence and reducing treatment burden compared with existing therapies. Overall, FXIIa inhibition with Garadacimab represents a promising upstream prophylactic strategy for HAE, addressing key limitations of current treatments and offering durable disease control. Further real-world and comparative studies are needed to define its long-term role in clinical practice and broader applicability in contact system–mediated disorders.

  • Dark side of nocturnal eating: Unraveling the emerging axis between meal timing, gut microbiota, and early-onset cancer risk

    by Saim Mahmood Khan, Jawairya Muhammad Hussain, Barina Khan, Abdullah Saad, Jaweria Mehboob, Gul Rukh, Malaika Manzoor, Ashal Waseem Mughal, Anusha Kayani, Mohammad Ali Baig, et al.